Prademagene Zamikeracel
Last Updated: 09/19/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa.
Journal: Expert opinion on biological therapy
Published: March 01, 2026
Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.
Journal: Pediatric dermatology
Published: September 16, 2025
Scaffold-free cell sheet therapies: clinical advances, global approval landscapes, and strategic directions to address regenerative medicine barriers.
Journal: Stem cell research & therapy
Published: September 15, 2025
Prademagene Zamikeracel: First Approval.
Journal: Molecular diagnosis & therapy
Published: July 13, 2025
Prademagene zamikeracel (Zevaskyn) for recessive dystrophic epidermolysis bullosa.
Journal: The Medical letter on drugs and therapeutics
Published: July 12, 2025
Prademagene Zamikeracel.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: June 25, 2025
FDA approval of prademagene zamikeracel (Zevaskyn): advancing gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) patients.
Journal: Annals of medicine and surgery (2012)
Published: May 29, 2025
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: January 06, 2025
Showing 1-8 of 8
Last Updated: 09/19/2026